| abstract |
Disclosed are a human-derived single-chain antibody against the complement C3d molecule and a fusion protein of said single-chain antibody and complement inhibitor DAF; said antibody has excellent antigen binding activity, and biological distribution experiments prove that the fusion protein provided by the present invention can quickly accumulate in an arthritic part after entering a rheumatoid arthritis mouse model, and has excellent anti-adhesive/anti-inflammatory targeting inhibitory effects. In the treatment of MRL/lpr lupus erythematosus mice, the fusion protein provided by the present invention can significantly improve the survival rate of mice, and furthermore, the symptoms of proteinuria, glomerular score, interstitial inflammation, vasculitis, and crescent/necrosis in the treatment group are significantly improved, demonstrating that the fusion protein provided by the present invention has excellent prospects for application in the preparation of autoimmune disease therapeutic drugs. |